Article
Immunology
Dan-Ni Li, Wen-Qing Lu, Bo-Wen Yang, Ling-Yun Zhang, Bo Jin, Shuo Wang, Xiao-Fang Che, Ce Li, Yun-Peng Liu, Xiu-Juan Qu
Summary: Indirect comparison suggested that atezolizumab monotherapy might be a more suitable treatment option for patients with advanced NSCLC and high PD-L1 expression compared to the combination of atezolizumab with chemotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
David G. Coffey, Yuexin Xu, Andrea M. H. Towlerton, Marcin Kowanetz, Priti Hegde, Martine Darwish, Mahesh Yadav, Craig Blanchette, Shannon M. Ruppert, Sarah Bertino, Qikai Xu, Andrew Ferretti, Adam Weinheimer, Matthew Hellmann, Angel Qin, Dafydd Thomas, Edus H. Warren, Nithya Ramnath
Summary: This article reports the clinical history of an exceptional responder with metastatic non-small cell lung cancer who achieved a complete and enduring remission after treatment with radiation and atezolizumab, an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody. The study reveals oligoclonal T cell expansion and tumor reactivity in the patient, suggesting that the exceptional response may be attributed to increased tumor immunogenicity promoted by radiation therapy and the persistence of expanded T cell clones.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Gerd Jomrich, Dagmar Kollmann, Dariga Ramazanova, Robin Ristl, Richard P. Grose, Ayseguel Ilhan-Mutlu, Matthias Preusser, Christina Fassnacht, Yi-Chien Tsai, Emmanuella Guenova, Sebastian F. Schoppmann
Summary: This study investigated the impact of neoadjuvant chemotherapy on the expression of PD-1 and PD-L1 in adenocarcinomas of the gastroesophageal junction. The results showed a significant increase in PD-1 expression and a decrease in PD-L1 expression after neoadjuvant therapy. These findings suggest that the combined use of cytotoxic chemotherapy and PD-1 axis blockade may be beneficial for patients with adenocarcinomas of the gastroesophageal junction.
Article
Oncology
Bo Xu, Huihui Cheng, Kunhong Li, Yukai Lv, Xianshang Zeng, Tao Liu, Weiguang Yu, Wenbo Guo
Summary: This retrospective review compared the efficacy and safety of atezolizumab plus carboplatin and nab-paclitaxel regimen versus carboplatin and nab-paclitaxel regimen for treatment-naive, metastatic nonsquamous PD-L1-positive NSCLC. The study found that ACN regimen had better overall survival and progression-free survival, but had more adverse events.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Zaishang Li, Xueying Li, Wayne Lam, Yabing Cao, Hui Han, Xueqi Zhang, Jiequn Fang, Kefeng Xiao, Fangjian Zhou
Summary: Comparing anti-PD-1 and anti-PD-L1 therapies in platinum-resistant UC patients reveals that anti-PD-1 therapy exhibits better antitumor activity, with comparable safety profiles and survival outcomes. This systematic comparison may enhance treatment awareness in this patient population.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Topias Karjula, Hanna Elomaa, Anne Niskakangas, Olli Mustonen, Iiris Puro, Teijo Kuopio, Maarit Ahtiainen, Jukka-Pekka Mecklin, Toni T. Seppala, Erkki-Ville Wirta, Eero Sihvo, Juha P. Vayrynen, Fredrik Yannopoulos, Olli Helminen
Summary: The study found that CD3(+) and CD8(+) T-cell density and PD-1/PD-L1 expression have prognostic value in pulmonary metastases of colorectal cancer. T-cell infiltration is higher in pulmonary metastases compared to primary tumors. High CD3(+) and CD8(+) cell density are associated with better survival, while high PD-L1 expression is associated with favorable prognosis.
Article
Pharmacology & Pharmacy
Fengze Sun, Dawei Wang, Aina Liu, Tianqi Wang, Dongxu Zhang, Huibao Yao, Kai Sun, Zhongbao Zhou, Guoliang Lu, Jitao Wu
Summary: PD-1 inhibitors demonstrate promising tolerance and efficacy in advanced urothelial carcinoma, but combination therapy with chemotherapy leads to more grade 3-4 adverse events.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Maofen Jiang, Chunjiao Liu, Dongxiao Ding, Hui Tian, Chaoqun Yu
Summary: This study aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer (NSCLC) patients and determine the optimal therapeutic regimen through network meta-analysis. The results showed that atezolizumab, cemiplimab, nivolumab, and pembrolizumab significantly improved overall survival compared to chemotherapy. Additionally, cemiplimab may have the most favorable risk-benefit ratio and ranked first in terms of efficacy and safety.
FRONTIERS IN ONCOLOGY
(2022)
Article
Respiratory System
Masanori Harada, Hyogo Naoi, Kazuyo Yasuda, Yutaro Ito, Namio Kagoo, Tsutomu Kubota, Koshiro Ichijo, Eisuke Mochizuki, Masahiro Uehara, Shun Matsuura, Masaru Tsukui, Naoki Koshimizu
Summary: This case report discusses a 65-year-old man diagnosed with kidney neuroendocrine carcinoma who developed eosinophilic granulomatosis with polyangiitis following treatment with a PD-1 inhibitor. The study highlights the potential risk of allergic inflammation associated with PD-1 blockade and the need for further research on its specific mechanisms.
BMC PULMONARY MEDICINE
(2021)
Review
Oncology
Chen Zhang, Qing Yang
Summary: Our meta-analysis of 55 studies found that high PD-L1 expression is not significantly associated with overall survival, progression-free survival, recurrence-free survival, cancer-specific survival, and disease-free survival in gynecological cancers. However, subgroup analysis revealed that high PD-L1 expression may be correlated with a shorter overall survival in some cases. Additionally, PD-L1 positivity was associated with certain clinical parameters and could potentially predict response to anti-PD-1/PD-L1 treatment.
FRONTIERS IN ONCOLOGY
(2021)
Review
Gastroenterology & Hepatology
Lin-Lin Zheng, Chang-Cheng Tao, Zong-Gui Tao, Kai Zhang, An-Ke Wu, Jian-Xiong Wu, Wei-Qi Rong
Summary: Recent years have seen success in phase III trials for targeted therapeutic agents in treating advanced hepatocellular carcinoma (HCC), with immunotherapy also considered effective. However, treating advanced HCC remains a challenge, highlighting the urgent need for new treatments.
WORLD JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Review
Immunology
Lin Zhang, Bo Hao, Zhihua Geng, Qing Geng
Summary: Toripalimab, a selective anti-PD-1 monoclonal antibody, has shown anti-tumor effects in melanoma, nasopharyngeal carcinoma, and urothelial carcinoma, and could be a valuable choice for future tumor treatment decision-making.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Adam P. Curnock, Giovanna Bossi, Jyothi Kumaran, Lindsay J. Bawden, Rita Figueiredo, Rajeevkumar Tawar, Katherine Wiseman, Emma Henderson, Sec Julie Hoong, Veronica Gonzalez, Hemza Ghadbane, David Eo Knight, Ronan O'Dwyer, David X. Overton, Christina M. Lucato, Nicola Mg Smith, Carlos R. Reis, Keith Page, Lorraine M. Whaley, Michelle L. McCully, Stephen Hearty, Tara M. Mahon, Peter Weber
Summary: The study developed PD-1 agonist ImmTAAI molecules that can inhibit T cell function by mimicking the action of PD-L1. These molecules specifically bind to target cells and effectively activate the PD-1 receptor on interacting T cells, achieving immune suppression.
Article
Pharmacology & Pharmacy
Taisuke Kaiho, Hidemi Suzuki, Atsushi Hata, Hiroki Matsumoto, Kazuhisa Tanaka, Yuichi Sakairi, Shinichiro Motohashi, Ichiro Yoshino
Summary: Immune checkpoint molecules, such as PD-1 and PD-L1, have been shown to be important in lung cancer treatment. This study explored the role of these proteins in acute rejection in a mouse model of tracheal transplantation and found that PD-L1 Fc recombinant protein could decrease inflammatory cytokines and reduce the proportion of CD4+ T cells, suggesting a potential novel target for immunotherapy in lung transplantation.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Immunology
Feng Xian, Dacheng Ren, Jun Bie, Guohui Xu
Summary: This meta-analysis demonstrates that high PD-L1/PD1 expression is associated with poor survival in patients with intrahepatic cholangiocarcinoma (ICC). PD-L1/PD1 may serve as a valuable prognostic and predictive biomarker, as well as a potential therapeutic target, for ICC.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
S. Peters, J-L Pujol, U. Dafni, M. Domine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Molla, R. Gervais, G. Lopez Vivanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J. L. Gonzalez Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-Voser, B. Ruepp, P. Mitchell, R. A. Stahel, C. Le Pechoux, D. De Ruysscher
Summary: The STIMULI trial did not demonstrate improvement in PFS with nivolumab-ipilimumab consolidation after chemo-radiotherapy in limited-disease small-cell lung cancer. The higher rates of grade >= 3 adverse events and treatment discontinuation in the experimental arm may have influenced the efficacy results.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Elodie Negre, Gerard Zalcman, Charlotte Domblides, Jeannick Madelaine, Jaafar Bennouna, Celine Mascaux, Denis Moro-Sibilot, Francois Pinquie, Alexis B. Cortot, Josiane Otto, Jacques Cadranel, Alexandra Langlais, Franck Morin, Virginie Westeel, Benjamin Besse
Summary: This study evaluated the efficacy of a triple therapy with HER2-targeted antibodies and docetaxel in HER2-mutated NSCLC patients, demonstrating feasibility and effectiveness of this approach, highlighting the potential benefit of HER2 antibody-based strategy in this subset of patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Naoyuki Nogami, Fabrice Barlesi, Mark A. Socinski, Martin Reck, Christian A. Thomas, Federico Cappuzzo, Tony S. K. Mok, Gene Finley, Joachim G. Aerts, Francisco Orlandi, Denis Moro-Sibilot, Robert M. Jotte, Daniil Stroyakovskiy, Liza C. Villaruz, Delvys Rodriguez-Abreu, Darren Wan-Teck Lim, David Merritt, Shelley Coleman, Anthony Lee, Geetha Shankar, Wei Yu, Ilze Bara, Makoto Nishio
Summary: This study presents the final overall survival (OS) analyses for EGFR mutations and liver or brain metastases subgroups in the IMpower150 study. The results show that ABCP has sustained OS improvements compared to BCP in sensitizing EGFR mutations and baseline liver metastases subgroups. However, ACP does not provide a survival benefit in these subgroups compared to BCP. The study also suggests further investigation into the impact of ABCP on delaying the development of new brain lesions.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Pierre-Jean Souquet, Clarisse Audigier-Valette, Olivier Molinier, Alexis Cortot, Jacques Margery, Lionel Moreau, Radj Gervais, Fabrice Barlesi, Eric Pichon, Gerard Zalcman, Patrick Dumont, Nicolas Girard, Michel Poudenx, Julien Mazieres, Jacques Cadranel, Didier Debieuvre, Jerome Dauba, Alexandra Langlais, Franck Morin, Denis Moro-Sibilot, Virginie Westeel, Maurice Perol
Summary: Adapting maintenance strategy according to response to induction chemotherapy does not improve patient outcome in advanced non-squamous non-small cell lung cancer.
Article
Medicine, General & Internal
Samy Lachkar, Mathieu Salaun, Loic Perrot, Diane Gervereau, Marielle De Marchi, Gurvan Le Bouar, Helene Morisse-Pradier, Stephane Dominique, Nicolas Piton, Florian Guisier, Luc Thiberville
Summary: This study suggests that radial endobronchial ultrasound (r-EBUS) is an effective and safe diagnostic technique for organizing pneumonia (OP), with a higher diagnostic yield when performed shortly after a CT scan showing a bronchus sign.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Radu Pirlog, Nicolas Piton, Aude Lamy, Florian Guisier, Ioana Berindan-Neagoe, Jean-Christophe Sabourin, Florent Marguet
Summary: Lung adenocarcinoma is the most common subtype of lung cancer, and the KRAS gene mutation is a frequent genomic alteration in these tumors. New clinical trials using targeted inhibitors for the specific KRAS G12C mutation showed promising results in a significant proportion of cases. In this study, genomic analysis was performed to identify molecular subtypes that may be more susceptible to therapy with KRAS G12C inhibitors.
Article
Oncology
Elodie Maille, Jerome Levallet, Fatemeh Dubois, Martine Antoine, Claire Danel, Christian Creveuil, Julien Mazieres, Jacques Margery, Laurent Greillier, Valerie Gounant, Denis Moro-Sibilot, Olivier Molinier, Herve Lena, Isabelle Monnet, Emmanuel Bergot, Alexandra Langlais, Franck Morin, Arnaud Sherpereel, Gerard Zalcman, Guenaelle Levallet
Summary: This study suggests that high cytosolic AREG expression is associated with better prognosis in malignant pleural mesothelioma (MPM). However, tumor cells fail to correctly process and release AREG, leading to inconsistency between its expression in plasma and tumor cells. Therefore, mesothelioma cell AREG content may serve as a prognostic marker.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Renaud Descourt, Maurice Perol, Gaelle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Marie Wislez, Jacques Cadranel, Alexis Benjamin Cortot, Florian Guisier, Loick Galland, Pascal Do, Roland Schott, Eric Dansin, Jennifer Arrondeau, Jean-Bernard Auliac, Margaux Geier, Christos Chouaid
Summary: This analysis evaluates the efficacy of brigatinib in ALK(+) advanced non-small cell lung cancer patients, with a focus on post-brigatinib lorlatinib efficacy. The results show that brigatinib is effective in heavily pretreated patients and lorlatinib demonstrates activity after brigatinib.
Article
Oncology
N. Girard, S. Galland-Girodet, V Avrillon, B. Besse, M. Duruisseaux, J. Cadranel, J. Otto, A. Prevost, B. Roch, J. Bennouna, K. Bouledrak, M. Coudurier, T. Egenod, R. Lamy, C. Ricordel, D. Moro-Sibilot, L. Odier, J. Tillon-Strozyk, G. Zalcman, P. Missy, V Westeel, S. Baldacci
Summary: This study investigates the efficacy and safety of lorlatinib in patients with ROS1-rearranged non-small-cell lung cancer (ROS1thorn NSCLC) treated through an expanded access program. The results suggest that lorlatinib is a major treatment option for advanced refractory ROS1thorn NSCLC in the treatment strategy.
Article
Oncology
Francois Montagne, Zied Chaari, Benjamin Bottet, Matthieu Sarsam, Frankie Mbadinga, Jean Selim, Florian Guisier, Andre Gillibert, Jean-Marc Baste
Summary: The study found that robotic-assisted thoracoscopic surgery (RATS) did not show superiority over video-assisted thoracoscopic surgery (VATS) for resectable non-small cell lung cancer (NSCLC).
Article
Oncology
Florian Guisier, Renaud Descourt, Helene Babey, Eric Huchot, Lionel Falchero, Remi Veillon, Alexis B. Cortot, Claire Tissot, Christos Chouaid, Chantal Decroisette
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Samy Lachkar, Loic Perrot, Diane Gervereau, Marielle De Marchi, Helene Morisse Pradier, Edouard Dantoing, Nicolas Piton, Luc Thiberville, Florian Guisier, Mathieu Salaun
Summary: This study evaluated the standardized procedure of first-line radial-endobronchial ultrasound (r-EBUS) and virtual bronchoscopy planner for the diagnosis of peripheral lung cancer. The results showed that r-EBUS and VB planner can be used as a first-line procedure to assess peripheral lung cancer due to its ease of perform, cost-effectiveness, and efficiency.
Article
Oncology
Samy Lachkar, Quentin Faur, Florent Marguet, Liana Veresezan, Michael Bubenheim, Mathieu Salaun, Luc Thiberville, Jean-Christophe Sabourin, Florian Guisier, Nicolas Piton
Summary: This study aimed to assess the improvement in diagnostic yield with the combination of EBUS-TBNA and EBUS-IFB compared to EBUS-TBNA alone. The results showed that the diagnostic yield was 94% when EBUS-IFB was combined with EBUS-TBNA, compared to 77% with EBUS-TBNA alone. In terms of histology, the diagnostic yield for nonmalignant conditions was 92% with the combination, compared to 69% with EBUS-TBNA alone.
Review
Oncology
Benjamin Bottet, Nicolas Piton, Jean Selim, Matthieu Sarsam, Florian Guisier, Jean-Marc Baste
Summary: Lung cancer is a heterogeneous disease that presents significant challenges in diagnosis and treatment. Recent advances in surgery, perioperative management, and targeted therapy have revolutionized the treatment landscape for this disease, offering new hope for patients. This review aims to provide a comprehensive understanding of the latest surgical approaches in lung cancer and emphasizes the importance of integrating these modalities within a patient-centered and personalized treatment pathway.
Article
Oncology
Sebastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier
Summary: The ROS-1 gene is pivotal in the oncogenesis of various tumors, and targeting ROS-1 with tyrosine kinase inhibitors can effectively inhibit tumor growth. Crizotinib is the current first-line therapy with promising results, but newer ROS-1-targeting TKIs have been developed for improved efficacy.